Peptides researched for
PCOS / ovarian metabolic
2 peptides · 4 studies
What people research this for
PCOS can bring weight gain, irregular cycles, and blood sugar trouble. Many women want help with the weight and metabolism side of it. The peptide research here is about weight and blood sugar, not fertility.
Researched for
- Weight with PCOS
- Blood sugar and insulin
- Metabolic health
What the studies say so far
Liraglutide and semaglutide have large randomized trials for weight and blood sugar. Those trials were run in people with excess weight, and doctors often bring them up when talking about PCOS because the problems overlap. Whether a medicine is approved for PCOS itself depends on the medicine and the country. This page does not cover fertility treatment.
Peptides studied
Each peptide below has been studied in this area. The label shows how far that research has gone.
Liraglutide
Tested in clinical trialsRandomized trial in people · 2 studies
Study note. Liraglutide weight and metabolic RCTs are frequently cited in PCOS metabolic-comorbidity discussions, fertility claims are out of scope here.
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (opens in a new tab)
Garvey WT, Birkenfeld AL, Dicker D · Diabetes care · 2020 · PubMed
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE) (opens in a new tab)
Pi-Sunyer X, Astrup A, Fujioka K · N Engl J Med · 2015 · PubMed
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial (opens in a new tab)
Semaglutide
Tested in clinical trialsRandomized trial in people · 2 studies
Study note. Semaglutide obesity trial data inform metabolic risk management conversations that often overlap with PCOS.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (opens in a new tab)
Wilding JPH, Batterham RL, Calanna S · N Engl J Med · 2021 · PubMed
- WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information (opens in a new tab)
Novo Nordisk · FDA Drug Label · 2021 · FDA label
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (opens in a new tab)
Look this up in the PeptIQ app
The app has the same research and sources, next to the tools you use to track your own protocol.
Related research
Insulin resistance / metabolic dysfunction
Weight, metabolism and hormones · 4 peptides
Obesity / weight management
Weight, metabolism and hormones · 4 peptides
NASH / MASLD (fatty liver)
Weight, metabolism and hormones · 2 peptides
HIV-associated lipodystrophy / visceral fat
Weight, metabolism and hormones · 1 peptide
Male hypogonadism / low testosterone
Weight, metabolism and hormones · 3 peptides